The FDA has refused to review Moderna’s application for its messenger RNA-based influenza vaccine, according to the company.In a press release, Moderna noted that the FDA’s rejection of the vaccine, ...

New questions about lung cancer in ‘never-smokers’ As the number of people who smoke has gone down over the decades, those who never smoked have begun to make up a greater proportion of lung cancer ...

Ocular Therapeutix's current wet AMD treatment is dominated by anti-VEGF drugs, with EYLEA holding a 63% global market share ...

Colorado hasn’t received notice of the canceled grants and can’t comment on the amount of lost funding or what projects it will affect.

Sustained interest in small molecules, bispecific antibodies, and genomics got the ball rolling in the biotech deals arena in ...

The Food and Drug Administration has refused to review an application from the biotech company Moderna to approve its ...

In an interview, Moderna President Stephen Hoge took questions on an FDA decision on the biotech's mRNA flu vaccine, as well ...

PROFIT: The pharmaceutical company is expected to report a loss of $1.02 billion, or $2.54 a share, according to analysts polled by FactSet. That compares with a loss of $1.12 billion, or $2.91 a ...

The Food and Drug Administration last week refused to review Moderna’s application for its messenger RNA flu vaccine, in a ...

The U.S. Food and Drug Administration is refusing to consider Moderna’s application for a new flu vaccine made with mRNA ...

President Sheinbaum announced on Monday the signing of an agreement between Mexico's Health Ministry, state-owned medical ...

News is latest sign of the agency's heightened scrutiny of vaccines ...